title: Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.
abstract: Humoral immune responses against the "Cancer-Testis" (CT) antigen NY-ESO-1 are frequently observed in patients with NY-ESO-1 expressing tumors. This is in contrast to other known tumor antigens (TA) defined by antibody or cytotoxic T cell (CTL) reactivity, i.e., MAGE-1, MAGE-3, SSX2, Melan A, and tyrosinase. No NY-ESO-1 antibody has been detected in healthy controls and patients with NY-ESO-1 negative tumors. In this study, we have assessed the NY-ESO-1 serum antibody response in patients with NY-ESO-1 positive tumors of different histological types and stages using Western blotting and an ELISA. Of the 12 patients analyzed, 10 had demonstrable NY-ESO-1 antibodies at the start of the study. All patients were followed for changes in NY-ESO-1 antibody titers during the course of tumor treatment and clinical evolution. In 4 patients, an increase of NY-ESO-1 antibody titer was observed with progression of disease or extensive tumor necrosis under treatment. One patient showed a stable NY-ESO-1 antibody titer over 3 years along with gradual regression of a large tumor mass. In 5 patients, a decrease of NY-ESO-1 antibody was detected: in 1 patient after curative tumor resection, in 3 patients with partial regression of metastatic disease under chemo- and immunotherapy, and in another patient with a NY-ESO-1 negative tumor relapse. Our results indicate that the induction and maintenance of NY-ESO-1 antibody is dependent on the presence of NY-ESO-1 expressing tumors. Furthermore, changes in NY-ESO-1 antibody titers correlate with the evolution of NY-ESO-1 positive disease.
authors.affiliation: II. Medizinische Klinik, Hämatologie-Onkologie, Krankenhaus Nordwest, Frankfurt, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Jäger
authors.forename: E
authors.initials: E
authors.lastname: Stockert
authors.forename: Z
authors.initials: Z
authors.lastname: Zidianakis
authors.forename: Y T
authors.initials: YT
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Karbach
authors.forename: D
authors.initials: D
authors.lastname: Jäger
authors.forename: M
authors.initials: M
authors.lastname: Arand
authors.forename: G
authors.initials: G
authors.lastname: Ritter
authors.forename: L J
authors.initials: LJ
authors.lastname: Old
authors.forename: A
authors.initials: A
authors.lastname: Knuth
mesh_terms: D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood*; D000951:Antigens, Neoplasm; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008545:Melanoma / Q000276:immunology; D008565:Membrane Proteins; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology*; D011506:Proteins / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013737:Testis / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D007074:Immunoglobulin G; D008565:Membrane Proteins; D011506:Proteins